Michael D Onken

Title: Michael D Onken: Innovator in Lysine Deacetylase Inhibitors

Introduction

Michael D Onken is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of biochemistry, particularly in the development of isoform-selective lysine deacetylase inhibitors. His work has implications for various medical applications, including cancer treatment and the management of chronic diseases.

Latest Patents

Michael D Onken holds a patent for isoform-selective lysine deacetylase inhibitors. These inhibitors target the lysine deacetylase enzyme, which plays a crucial role in several biological processes. The patent outlines their potential use as antitumor drugs and in treating conditions such as addiction, asthma, cardiovascular disease, immunosuppression, neurodegenerative diseases, sepsis, sickle-cell disease, uveal melanoma, and the termination of viral latency, particularly HIV-1 latency. He has 1 patent to his name.

Career Highlights

Michael D Onken is affiliated with Washington University, where he conducts research and develops innovative solutions in the field of biochemistry. His work has garnered attention for its potential to address significant health challenges.

Collaborations

Some of his notable coworkers include Garland R Marshall and George B Kyei. Their collaborative efforts contribute to advancing research in the field of lysine deacetylase inhibitors.

Conclusion

Michael D Onken's contributions to the development of isoform-selective lysine deacetylase inhibitors highlight his role as an innovator in biochemistry. His work has the potential to impact various medical fields significantly.